MA-BRIGHTCOVE
5.3.2024 15:04:33 CET | Business Wire | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced it is welcoming MotoAmerica, North America’s premier motorcycle road race series, to its roster of media customers. As the official streaming provider for MotoAmerica, Brightcove will power the live and video-on-demand (VOD) capabilities of the MotoAmerica Live+ streaming service, which will exclusively broadcast the upcoming 82nd running of the Daytona 200 (March 7-9, 2024).
“Delivering quality live and on-demand streaming experiences is essential for today’s sports and entertainment organizations to reach and engage their audiences effectively,” said Marc DeBevoise, CEO of Brightcove. “We’re happy to partner with MotoAmerica to help them deliver a unique viewing experience for fans worldwide. Through our award-winning platform, MotoAmerica will now be able to monetize its content on a global scale and drive additional revenue.”
“MotoAmerica began the journey into live-streaming motorcycle racing events in 2019. Throughout the years, we’ve received feedback from our fans to enhance the viewing experience,” said MotoAmerica COO Chuck Aksland. “In response, we decided to collaborate with Brightcove to offer our fans the upgraded experience they have been asking for. With the new platform provided by Brightcove, MotoAmerica can incorporate additional elements into the overall viewing experience. These elements include integrated live timing, betting options, news updates, merchandise offerings, and access to the 24-hour all-motorsports channel MTRSPT1, all in one location. Partnering with Brightcove ensures that both current and new fans of MotoAmerica can enjoy the best viewing experience possible. We are very excited about the improvements and are confident that our fans will appreciate the enhanced features and functionality now available to them.”
To tune in to MotoAmerica's action, fans can subscribe to MotoAmerica’s live streaming service, MotoAmerica Live+. Subscribers can watch races in all MotoAmerica classes live or on-demand and view highlights, interviews, and races from years past.
MotoAmerica joins a roster of professional sports organizations currently deploying Brightcove’s technology to connect with their fans, including Atlantic Coast Conference (ACC) Raycom Sports, ATP Tour, Badminton Horse Trials, Canadian Football League, Confederation of North, Central America and Caribbean Association Football (Concacaf), Harness Racing Victoria, Little League Baseball and Softball, Major League Soccer (MLS), National Hockey League (NHL), National Hot Rod Association (NHRA), U.S. Ski & Snowboard, United States Olympic and Paralympic Committee, United World Wrestling and USA Volleyball.
The addition of MotoAmerica further demonstrates Brightcove as the world’s leading streaming technology partner with a reliable, scalable, and flexible platform trusted by some of the most prominent sports entities in the world.
For more information, visit Brightcove.com.
About MotoAmerica
MotoAmerica is North America’s premier motorcycle road racing series. Established in 2014, MotoAmerica is home to the AMA Superbike Championship as well as additional classes, including Supersport, Stock 1000, Twins Cup, Junior Cup, and King Of The Baggers. MotoAmerica is an affiliate of KRAVE Group LLC, a partnership including three-time 500cc World Champion, two-time AMA Superbike Champion, and AMA Hall of Famer Wayne Rainey; ex-racer and former manager of Team Roberts Chuck Aksland; motorsports marketing executive Terry Karges; and businessman Richard Varner. For more information, please visit www.MotoAmerica.com and follow MotoAmerica on Facebook, Instagram, TikTok, Twitter, and YouTube.
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X (Formerly Twitter), Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305118283/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom